Our findings reveal that JOA could induce the differentiation of CML cells expressing BCR-ABL-T315I, which reveal that JOA may be a potent differentiation inducer for the treatment for CML patients with BCR-ABL mutations. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.